CHIMERIC THERAPEUTICS LIMITED — Director's Dealing 2023

Aug 27, 2023

ASX ANNOUNCEMENT

28 August 2023

==> picture [262 x 53] intentionally omitted <==

Late lodgement of Appendix 3Y

Attached is an Appendix 3Y – Change of Director’s Interest Notice for Paul Hopper.

The Company considers the late lodgement as an isolated incident which arose due to the proximity of the placement and share purchase plan of which Mr Paul Hopper participated in both. The results of the placement and share purchase plan were announced on 23 June 2023. The Company believes that its current practices are adequate to ensure compliance with the Corporations Act and ASX Listing Rules, however, it is exploring additional compliance monitoring with the share registry.

The Company and the Directors are aware of their obligations under the Corporations Act and ASX Listing Rules 3.19A and 3.19B to provide the necessary information to the Company to meet its disclosure requirements.

Phillip Hains Company Secretary

Chimeric Therapeutics Limited ABN 68 638 835 828 www.chimerictherapeutics.com

Appendix 3Y Change of Director’s Interest Notice

Late lodgement Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001. Ame	nded 01/01/11
	Chimeric Therapeutics Limited (ASX: CHM)
Name of Entity:
	68 638 835 828
ABN:

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Paul Hopper
Date of Last Notice:	17 July 2023

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

director” should be disclosed in this part.
Direct or Indirect Interest		Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.
Date of change		23 June 2023
No. of securities held prior to change				Options - 2,941,176 2,941,176
			Shares	Options
		Direct	375,000	-
		Indirect	93,762,432	2,941,176
		Total	94,137,432	2,941,176
Class		Fully Paid Ordinary Shares
Number acquired				Options - - -
			Shares	Options
		Direct	857,142	-
		Indirect	-	-
		Total	857,142	-
Number disposed				Options - - -
			Shares	Options
		Direct	-	-
		Indirect	-	-
		Total	-	-

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		$0.035 per share per SPP	$0.035 per share per SPP
No. of securities held after change				Options - 2,941,176 2,941,176
			Shares	Options
		Direct	1,232,142	-
		Indirect	93,762,432	2,941,176
		Total	94,994,574	2,941,176
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back		Participation in SPP announced on 15 May 2023.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

director” should be disclosed in this part.
Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Part 3 – Closed period

Were the interests in the securities or No contracts detailed above traded during a +closed period where prior written clearance was required? If so, was prior written clearance N/A provided to allow the trade to proceed during this period? If prior written clearance was N/A provided, on what date was this provided?

==> picture [39 x 23] intentionally omitted <==

The CFO Solution

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3